Previous studies in this and other laboratories have identified several antiviral compounds capable of inhibiting the replication of dengue viruses in a variety of tissue culture systems (6) (7) (8) 11) . The anti-influenza agents amantadine and rimantadine effectively reduce the growth of all four types of dengue viruses in LLC-MK2 cells and in human peripheral blood leukocytes (6, 7) . Based on minimal inhibitory concentration analyses, rimantadine appears to be more effective than amantadine in limiting the replication of dengue viruses in vitro (7) . Ribavirin, a broadspectrum antiviral agent, suppresses the growth of dengue viruses in LLC-MK2 cells but has no effect on dengue virus growth in human peripheral blood leukocytes (8) . In addition, it has been shown that ribavirin plus 6-mercapto-9-(tetrahydro-2-furyl)purine (6-MPTF) can significantly inhibit the replication of dengue viruses in human peripheral blood leukocytes at drug concentrations well below cytotoxic levels (8) .
In this present study, rimantadine, ribavirin, ribavirin 2',3',5'-triacetate (RTA), and 6 dengue virus-infected mice with ribavirin did not significantly affect the course of infection (group B, Table 1 ). RTA is a lipophilic analog' of ribavirin (2). When RTA was administered i.p. three times daily to dengue virus-infected BALB/c mice for a period of 7 days post-virus inoculation, it significantly increased the mean survival time (P < 0.01) and percent survival (P < 0.05) as compared with those of saline-treated control animals (groups B and C, Table 1 ). Previous studies in this laboratory have demonstrated a synergistic antiviral effect of ribavirin and 6-MPTF against dengue virus infections in vitro (7) . As a result of those studies, the chemotherapeutic efficacy of the combination of RTA and 6-MPTF against dengue virus infections in mice was evaluated. 6-MPTF alone or in combination with RTA was not effective in reducing dengue virus infections in mice, based on mean survival time and percent survival (group C, (6) . Using dosage levels comparable to those previously shown to be effective against influenza in mice and approximately 50% of the maximum tolerated dose (3), we conclusively demonstrated a lack of effect of rimantadine when administered i.p. against dengue virus infections in mice. This lack of efficacy might be due to an inability of rimantadine to cross the blood-brain barrier and reach the site(s) of viral infection.
Ribavirin is a nucleoside analog which exhibits antiviral efficacy against a substantial number of DNA and RNA viruses both in vitro and in vivo (9) . However, previous reports have demonstrated that ribavirin is not effective against intracerebral virus infections of mice, regardless of the viral nucleic acid type, unless the drug is administered directly into the brain (1). This suggests that ribavirin or its active metabolites do not reach the brain in adequate concentrations. Our data showing a lack of effect of ribavirin when administered i.p. to dengue virusinfected mice concur with the hypothesis that the drug probably does not cross the blood-brain barrier.
RTA is a derivative of ribavirin with a greater index of lipid solubility. In previous studies, RTA has been found to be superior to ribavirin in the treatment of influenza-infected mice (12) and against arenavirus-induced hemorrhagic fever in rhesus monkeys (11) . Because of its greater lipid solubility, RTA is more likely to pass through the blood-brain barrier and may act as a prodrug which is slowly hydrolyzed to ribavirin itself in vivo (2). Studies by Smee et al. (10) with Colorado tick fever virus infections supported this hypothesis of the propensity of RTA to cross the blood-brain barrier and suppress viral encephalitic disease. Our study demonstrates that RTA exhibits significant antiviral efficacy against dengue virus infections intracranially in mice when the drug is administered i.p. These encouraging results signal a need to further examine the efficacy of RTA against dengue viruses in subhuman primates, in which antiviral efficacy might be expected owing to the striking similarities in sites of virus replication between the dengue virus and arenavirus systems (4). 
